Infliximab in rheumatic diseases

dc.contributor.authorJanse van Rensburg, Dina Christina
dc.date.accessioned2014-07-04T06:40:12Z
dc.date.available2014-07-04T06:40:12Z
dc.date.issued2013-06
dc.descriptionIn this article no comparison with regards to long-term efficacy and safety was made to other biologic drugs.en_US
dc.description.abstractInfliximab (REVELLEX®) is a chimeric IgG1κ monoclonal antibody against tumor necrosis factor-α (TNF-α). Infliximab is indicated, for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD, ulcerative colitis (UC) and skin psoriasis. The first aim of this article is to revisit the indications for the use of Infliximab in RA, AS and PsA. The second aim is to get an update on the newest insights on the safety and efficacy of the drug.en_US
dc.description.librarianam2014en_US
dc.description.urihttp://www.media24.com/en/magazines/business-magazines/sa-rheumatology-journal.htmlen_US
dc.identifier.citationJanse van Rensburg, DC 2013, 'Infliximab in rheumatic diseases', South African Rheumatology Journal, vol. 5, no. 2, pp. 21-24.en_US
dc.identifier.urihttp://hdl.handle.net/2263/40539
dc.language.isoenen_US
dc.publisherMedia 24en_US
dc.rightsMedia 24en_US
dc.subjectInfliximaben_US
dc.subjectTumoren_US
dc.subjectTreatmenten_US
dc.subjectRheumatoid arthritisen_US
dc.titleInfliximab in rheumatic diseasesen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JanseVanRensburg_Infliximab_2013.pdf
Size:
2.24 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: